Discontinued — last reported Q3 '25
W.R. Berkley Equity Method Investments increased by 2.7% to $1.40B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.6%, from $1.48B to $1.40B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a 0.8% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.37B | $1.40B | $1.48B | $1.55B | $1.70B | $1.66B | $1.61B | $1.60B | $1.59B | $1.60B | $1.62B | $1.56B | $1.59B | $1.61B | $1.47B | $1.48B | $1.49B | $1.43B | $1.36B | $1.40B |
| QoQ Change | — | +2.3% | +5.7% | +4.4% | +10.1% | -2.4% | -3.2% | -0.4% | -0.5% | +0.4% | +1.3% | -4.1% | +2.1% | +1.1% | -8.7% | +0.8% | +0.8% | -4.1% | -4.8% | +2.7% |
| YoY Change | — | — | — | — | +24.3% | +18.6% | +8.6% | +3.6% | -6.3% | -3.7% | +0.8% | -2.9% | -0.3% | +0.4% | -9.5% | -4.9% | -6.1% | -11.0% | -7.2% | -5.6% |